Gilead Sciences wins $175m in ongoing HIV fraud case
March 13, 2023Sales and Marketing
Gilead Sciences, a research-based biopharmaceutical company, has won again in the lawsuit levelled against clinics, prescribers, medical labs and pharmacies …
Nasal spray that relieves migraines in minutes approved by FDA
March 13, 2023Medical Communications
Pfizer is planning to launch a fast-acting nasal spray that can relieve pain from migraines in as little as 15 …
Horizon Therapeutics announces real-world treatment results for Dysthyroid Optic Neuropathy drug
March 13, 2023Medical Communications
Biopharma company Horizon Therapeutics has announced real-world treatment results for its Thyroid Eye Disease (TED) drug in patients with Dysthyroid …
Biotech centre focusing on gene therapies opens in Bristol, UK
March 10, 2023Medical Communications
A new state-of-the-art facility named the Clinical Biotechnology Centre (CBC) is opening in Bristol, UK. It cost approximately £10m to …
FDA makes unusual ‘misinformation’ comment on Lucira’s EUA for COVID-19 and flu test
March 10, 2023Sales and Marketing
The FDA has made a rare comment about what happened at Lucira Health’s Emergency Use Authorization (EUA) filing for its …
Acadia Pharmaceuticals awaits FDA decision for first-of-its-kind Rett syndrome drug
March 10, 2023Research and Development
Acadia Pharmaceuticals is aiming to follow in the footsteps of Reata Pharmaceuticals, who won approval for its novel drug to …
FDA committee supports Roche’s lymphoma treatment
March 10, 2023Medical Communications
A committee at the FDA have voted in favour of Roche’s Polivy antibody drug targeting untreated diffuse large B cell …
FlyPharma Europe, Vienna: 2023 conference officially launched
March 9, 2023Business Services
FlyPharma Europe, Vienna: 2023 conference officially launched FlyPharma Conferences is pleased to announce its seventh event in Europe, which …
MSD presents Phase 3 data for its Investigational Activin Signaling Inhibitor, in Adults with Pulmonary Arterial Hypertension on Background Therapy
March 9, 2023Business Services
LONDON, UK, March 6, 2023 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK)) today announced …
GSK’s RSV vaccine ready to launch
March 9, 2023Sales and Marketing
GSK has announced that it is ready to launch its respiratory syncytial virus (RSV) vaccine in the US at some …
Eli Lilly & Co’s Alzheimer’s disease drug fails to stop disease decline
March 9, 2023Research and Development
Eli Lilly & Co have today announced that its Alzheimer’s disease (AD) hopeful did not slow the progression of cognitive …
AstraZeneca shares positive results from Imfinzi trial
March 9, 2023Research and Development
Pharma giant AstraZeneca has shared positive results from a phase 3 trial on Imfinzi, its resectable non-small cell lung cancer …
Respiree gets FDA clearance for cardio-respiratory wearable
March 9, 2023Medical Communications
Respiree, a digital therapeutics start-up, has secured the 510(k) FDA clearance for its RS001 cardio-respiratory wearable. RS001 is a …
New clinical trial aims to find new endometriosis treatment
March 8, 2023Research and Development
A new clinical trial is set to begin shortly which will be a collaboration between the universities of Edinburgh, Aberdeen …
Abbott’s concussion-detecting blood test approved by FDA
March 8, 2023Medical Communications
US-based Abbott, a medical technology company, has received FDA approval for its laboratory blood test which detects traumatic brain injury …
Hospital for Special Surgery reveals 3D surface topographic scan for scoliosis patients
March 8, 2023Medical Communications
Researchers at New York City’s Hospital for Special Surgery (HSS) have found that using a 30-camera array, or 3dMD, can …
FDA grants de novo approval to Neuromod’s tinnitus device
March 8, 2023Medical Communications
The FDA has granted de novo approval to Neuromod’s Lenire device which includes Bluetooth headphones, a handheld controller and the …
Redx Announces RXC004 Topline Data From a Phase 2 Monotherapy Module
March 8, 2023Business Services
Alderley Park, UK, 8 March 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, …
POLB 001 patent portfolio strengthened through granting of US patent
March 8, 2023Business Services
8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical …
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
March 7, 2023Business Services
Parma, Italy and Solna, Sweden, March 7th, 2023 – Chiesi Farmaceutici S.p.A (“Chiesi Group”) and Affibody AB (“Affibody”) today announced …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
